The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Our ability to treat diseases previously untreatable through the delivery of adeno-associated virus (AAV)-based gene therapies has been a tremendous advancement in pharmaceutical development…
In addition to the now well-known CAR T (chimeric antigen receptor T cells) and HSC (CD34+ hematopoietic stem cells) cell-based gene therapies, there are several other modes of gene modification as well as cell types already approved and on the horizon…